GBM or DIPG – This is how ONC201 can be obtained as compassion
Intended for recurrent Glioblastoma, GBM, patients or patients with DIPG brain tumor with H3 K27M mutation We will be happy to help you access the world's most advanced treatments both…
Intended for recurrent Glioblastoma, GBM, patients or patients with DIPG brain tumor with H3 K27M mutation We will be happy to help you access the world's most advanced treatments both…
No sign of cancer! Groce has been a part of a clinical trial since his diagnosis four-plus years ago and the results have been tremendous –just recently, his MRI and…
Background The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life…
PURPOSE OF THE STUDY The trial was designed to evaluate the safety and efficacy of adding Capivasertib to Taxol as first-line therapy for metastatic TNBC patients. PATIENTS AND METHODS A…
Background This phase II trial was designed to evaluate the benefit of Keytruda® plus Zolinza® for recurrent Head and Neck Squamous Cell Carcinoma, HNSCC and Salivary Gland Cancer, SGC. Among…
Background Urothelial cancer accounts for 90% of all bladder cancers and can also be found in the renal pelvis, ureter and urethra. Tremelimumab is an immunotherapy treatment that helps the…
Background Metastatic colorectal cancer, mCRC, is a group of distinct diseases, with clinical and molecular differences between right-sided and left-sided tumors driving varying prognosis. Patients with KRAS/RAS-wild type (wt) mCRC…
When was it reported? The outcome of the phase II, multicenter, open-label, single-arm DESTINY-Breast trial was reported at the 2019 San Antonio Breast Cancer Symposium, SABCS, from December 10 –…
In short The results of a phase II trial in patients with BRAF V600E mutations in high- and low-grade glioma, were reported at the 24th meeting of the Society for…
Interim results The virus has been designated a breakthrough therapy in Japan. An interim analysis of a trial of the oncolytic herpes virus G47∆ has shown a 1-year survival rate…